Emergingby GlyphBioAge reports interim Phase 1 data for NLRP3 inhibitor BGE-102
BGE-102 was well tolerated in dose cohorts and supported once-daily oral dosing.
Longevity biotechsec.gov
BioAge Labs
Public companyUS1 field
Where it works
| Technology | ||
|---|---|---|
| Longevity biotechUses human aging biology to develop cardiometabolic drugs, including the NLRP3 inhibitor BGE-102. | Uses human aging biology to develop cardiometabolic drugs, including the NLRP3 inhibitor BGE-102. | bioagelabs.com |
Events
BioAge Labs prices its Nasdaq IPO
BioAge sold 11 million shares at $18.00 each and listed under the ticker BIOA.
Longevity biotechsec.gov
Funding
About
- Source
- bioagelabs.com (official, added by seed)
- First seen
- Sep 25, 2026
- Last seen
- Oct 6, 2026
- Across Glyph
- BioAge Labs on Companies
BioAge Labs
Joined in Longevity biotech. Uses human aging biology to develop cardiometabolic drugs, including the NLRP3 inhibitor BGE-102.
BioAge Labs
Added in Longevity biotech. Uses human aging biology to develop cardiometabolic drugs, including the NLRP3 inhibitor BGE-102.